Menu
Search
|

Menu

Close
X

Atara Biotherapeutics Inc ATRA.OQ (NASDAQ Stock Exchange Global Select Market)

39.95 USD
-1.75 (-4.20%)
As of Jul 13
chart
Previous Close 41.70
Open 41.65
Volume 104,700
3m Avg Volume 229,349
Today’s High 42.00
Today’s Low 39.05
52 Week High 54.45
52 Week Low 12.75
Shares Outstanding (mil) 43.95
Market Capitalization (mil) 1,755.78
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.14 Mean rating from 7 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
FY15
0
EPS (USD)
FY18
-1.047
FY17
-3.993
FY16
-2.750
FY15
-2.211
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.20
Price to Sales (TTM)
vs sector
--
8.07
Price to Book (MRQ)
vs sector
3.99
4.28
Price to Cash Flow (TTM)
vs sector
--
22.38
Total Debt to Equity (MRQ)
vs sector
0.00
17.39
LT Debt to Equity (MRQ)
vs sector
0.00
13.21
Return on Investment (TTM)
vs sector
-39.44
13.23
Return on Equity (TTM)
vs sector
-40.24
15.28

EXECUTIVE LEADERSHIP

Isaac Ciechanover
Chairman of the Board, President, Chief Executive Officer, Since 2016
Salary: $562,380.00
Bonus: $320,503.00
Utpal Koppikar
Chief Financial Officer, Since 2018
Salary: --
Bonus: --
Joseph Newell
Executive Vice President, Chief Technical Operations Officer, Since 2017
Salary: $258,750.00
Bonus: $191,946.00
Christopher Haqq
Executive Vice President - Research and Development, Chief Scientific Officer, Since 2012
Salary: $416,000.00
Bonus: $154,752.00
Mitchall Clark
Executive Vice President and Chief Regulatory and Quality Assurance Officer, Since 2014
Salary: $231,806.00
Bonus: $90,620.00

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

611 Gateway Blvd Ste 900
SOUTH SAN FRANCISCO   CA   94080-7015

Phone: +1650.2788930

Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells. T-cells are a type of white blood cell. The Company's product candidate, ATA129, is a third-party derived Epstein-Barr virus CTL for the treatment of Epstein-Barr virus (EBV). ATA188 is in development for the treatment of multiple sclerosis. ATA520, which is a third-party donor derived WT1-CTL, targets cancers expressing the antigen Wilms Tumor 1 (WT1). ATA520 is in Phase I clinical trials. The Company's T-cell product candidate, ATA230, which is a third-party derived cytomegalovirus-CTL (CMV-CTL), is in Phase II clinical trials for refractory CMV.

SPONSORED STORIES